Elevated Serum or Plasma Sodium
Excessive parenteral sodium administration in an unconscious patient whose thirst mechanism is absent.
Excessive use of diuretics or other drugs leading to water loss in the patient who cannot compensate by intake of water.
Diabetes insipidus may be central (neurogenic), acquired nephrogenic, or congenital nephrogenic.
Mineralocorticoid or glucocorticoid excess from primary hyperaldosteronism and Cushing syndrome with or without ectopic adrenocorticotropic hormone (ACTH) production.
Insensible water loss through the skin in the patient unable to obtain water or swallow.
Clinical findings progress from somnolence to confusion, coma, and respiratory paralysis as the hypernatremia worsens.
Commonly Encountered Situations
Hypernatremia most frequently occurs in an ICU when excess intravenous (IV) sodium is given to an unconscious patient.
Suggested Additional Lab Testing
Urinary electrolytes to assess for diabetes insipidus.
Serum aldosterone to identify primary hyperaldosteronism 24-hour urine free cortisol to identify Cushing syndrome, with or without ectopic ACTH production.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Weight Gain After Quitting Smoking May Increase Risk for T2D
- In Teens, Young Adults, High BMI May Hurt Cardiovascular Health
- Obesity Paradox Affects Type 2 Diabetes Mortality Rates
- Bi-Directional Association Observed Between Obstructive Sleep Apnea and Diabetes
- Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis